查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
2018847

神经血管介入器材市场：依产品类型、适应症、手术类型及最终用户划分－2026年至2032年全球市场预测

Neurovascular Intervention Devices Market by Product Type, Indication, Procedure Type, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，神经血管介入器材市场价值将达到 45.3 亿美元，到 2026 年将成长至 48.4 亿美元，到 2032 年将达到 71.4 亿美元，复合年增长率为 6.69%。

主要市场统计数据
基准年 2025 45.3亿美元
预计年份：2026年 48.4亿美元
预测年份 2032 71.4亿美元
复合年增长率 (%) 6.69%

对神经血管设备的最新创新、临床应用驱动因素以及影响相关人员决策的策略考量进行了清晰而令人信服的概述。

神经血管介入器材市场格局正迅速演变，这主要得益于器械工程、影像技术和急诊护理方案的整合发展。近年来，临床医生和器械研发人员已从渐进式改进转向平台级创新，从根本上改变了复杂脑血管疾病的诊断、治疗和管理方式。这种转变使得相关人员比以往任何时候都更需要了解产品层面的差异化因素，以及手术流程、报销趋势和临床偏好如何相互作用，进而影响器械的普及和治疗效果。

材料科学的突破、诊断影像技术的整合以及不断发展的医疗保健服务模式，是如何改变神经血管治疗中的设备应用和临床路径的？

神经血管介入器材领域正经历变革性的转变，其影响不仅限于器械本身的改进，也延伸到手术流程和医疗服务模式的革新。材料科学的突破和设计的改进提升了器械的疗效和安全性，使临床医生能够应对以往难以处理的解剖结构和复杂病变形态。同时，影像整合和导航系统的增强缩短了手术时间，提高了器械植入的精确度。因此，符合这些治疗条件的患者范围扩大，临床医师对先进介入治疗的信心也随之增强。

评估新关税政策对神经血管器械相关人员。

自2025年起，对某些医疗设备组件和成品征收关税将进一步增加神经血管器械相关人员的采购和供应链的复杂性。拥有全球製造地的製造商被迫重新评估其筹资策略和成本结构，以缓解利润率下降并维持价格竞争力。因此，医疗系统和集团采购组织的采购团队正在权衡短期成本增加与长期临床价值之间的利弊，尤其对于那些能够显着缩短手术时间、降低併发症发生率或减少后续护理需求的器械而言。

整合细分洞察，揭示产品类型、临床适应症、医疗保健环境和手术类型如何共同决定采用趋势和商业性重点。

透过整合产品、适应症、终端用户和手术流程观点，市场区隔框架提供了切实可行的洞察。根据产品类型，每种装置类别——栓塞剂、血流导向装置、微导管、神经血管弹簧圈、支架和血栓除去装置装置——都展现出不同的临床和商业性动态。在栓塞剂领域，液态栓塞剂和颗粒状栓塞剂之间的差异会影响手术技术、储存和处理注意事项以及临床应用案例。血流导向装置则提供了差异化的价值提案，例如“Pipeline栓塞装置”和“Surpass血流导向装置”，其输送方式、径向力和内皮化特性方面的差异会影响临床医生的选择。微导管的涂层，无论是亲水性涂层或聚合物涂层，都会改变操作者所依赖的触感和导航特性。同时，在弹簧圈技术方面，可脱卸式弹簧圈和推入式弹簧圈在展开控制和重新定位方面各有优劣。球囊扩张式支架和自膨式支架平台在病灶准备和部署流程上有显着差异，血栓切除策略也分为抽吸装置和血栓摘取支架两种。每种平台都有其独特的手术成功模式，这会影响医疗机构的采购决策。

区域比较趋势揭示了法规环境、支付方结构和临床网路如何引导不同的产品引进和商业化路径。

神经血管介入治疗的区域趋势反映了法律规范、医疗保健系统结构和临床实践模式的差异。在美洲，先进的中风系统和健全的三级医疗网络正在推动血管内治疗方案的快速普及，尤其註重院前分诊和院间转运流程的整合，以最大限度地提高及时干预的效率。该地区通常为新器械的早期应用提供有利环境，前提是这些器械拥有强有力的临床证据和卫生经济学论点。此外，支付方也越来越重视疗效比较，并将其纳入保险覆盖范围的决策考量。

透过临床证据、生产灵活性和与医疗保健系统优先事项的策略一致性来决定市场领导地位的竞争与合作动态。

神经血管介入领域的竞争动态是由成熟的医疗设备创新者、新兴的专业公司以及垂直整合的医疗技术公司共同塑造的。主要企业通常会投入巨资进行医疗设备的迭代改进、开展严谨的临床试验项目并製定广泛的培训倡议，以缩短医务人员的学习曲线，并加速其在医疗机构中的应用。同时，小规模、反应更灵活的公司则经常推出差异化的材料和给药机制，挑战现有厂商并推动品类扩张。这种趋势在一些特定的解剖部位和手术流程中尤其明显，因为在这些领域，即使是微小的改善也能带来极其显着的临床效益。

为确保产品设计、证据产生和商业性执行的可持续采用和价值，提供切实可行的策略和营运建议。

产业领导者应采取协调一致的策略，将产品开发、证据产生和商业性执行有机结合，以加速产品上市并维持市场地位。优先考虑能够优化输送能力和手术效率的设计选择，将引起注重缩短手术时间和提高安全性的临床医生的共鸣。同时，投资可靠的真实世界证据（RWE）项目和卫生经济学分析至关重要，这有助于说服采购委员会和支付方，让他们相信医疗设备的选择将显着降低整体医疗保健成本。

透明且多方面的研究途径，结合专家访谈、文献整合和情境测试，确保获得可靠且可操作的见解。

本分析的调查方法融合了多种定性和定量方法，以确保其严谨性和有效性。关键资料来源包括对临床专业人员、采购经理和产业主管的结构化访谈，从而深入了解治疗流程、推广驱动因素和采购决策标准。这些访谈内容与同行评审的临床文献、监管申报文件和会议论文集进行交叉比对，以检验疗效声明并识别新兴的临床共识。

整合作为结论：将设备创新、实证策略和营运韧性连结起来，作为实现永续影响和竞争优势的关键要素。

总而言之，神经血管介入领域正从渐进式改善转向变革性创新，重塑临床路径、采购行为和竞争动态。器械设计和手术技术的进步正在扩大治疗可能性并改善治疗效果，但成功的商业化越来越需要整合临床证据、供应链韧性和支付方合作的综合策略。展望2025年的收费系统，灵活的筹资策略和更清晰地展示整体拥有成本（TCO）效益对于维持市场准入和促进临床医生采纳至关重要。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 神经血管介入器材市场：依产品类型划分

  • 栓塞剂
    • 液态栓塞剂
    • 颗粒栓子
  • 分流器
    • 管道栓塞装置
    • 超流分流器
  • 微导管
    • 亲水涂层
    • 聚合物涂层
  • 神经血管线圈
    • 可拆卸线圈
    • 推式线圈
  • 支架
    • 气球式
    • 自膨胀
  • 血栓除去装置
    • 吸力装置
    • 血栓摘取支架

第九章 神经血管介入器材市场：依适应症划分

  • 动脉瘤
  • 动静脉畸形
  • 中风

第十章：依治疗类型分類的神经血管介入器材市场

  • 栓塞术
  • 血流改道
  • 血栓切除术

第十一章 神经血管介入器材市场：依最终用户划分

  • 门诊部
  • 诊所
  • 医院

第十二章 神经血管介入器材市场：按地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章 神经血管介入器材市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 神经血管介入器材市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章：美国神经血管介入器材市场

第十六章：中国神经血管介入器材市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Abbott Laboratories
  • Acandis GmbH
  • Balt Group
  • Becton, Dickinson and Company
  • Boston Scientific Corporation
  • Carl Zeiss AG
  • Evasc Medical Systems Corp.
  • GE Healthcare
  • Imperative Care Inc.
  • Japan Lifeline Co.
  • Johnson & Johnson Services, Inc.
  • Kaneka Corporation
  • Koninklijke Philips NV
  • LivaNova PLC
  • Medikit Co., Ltd.
  • Medtronic plc
  • MicroPort Scientific Corporation
  • MicroVention, Inc.
  • Nanoflex Robotics AG
  • Penumbra, Inc.
  • Phenox GmbH by Wallaby Medical, LLC
  • Rapid Medical Ltd.
  • Stryker Corporation
  • Terumo Corporation
Product Code: MRR-ED54C46E8FA1

The Neurovascular Intervention Devices Market was valued at USD 4.53 billion in 2025 and is projected to grow to USD 4.84 billion in 2026, with a CAGR of 6.69%, reaching USD 7.14 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 4.53 billion
Estimated Year [2026] USD 4.84 billion
Forecast Year [2032] USD 7.14 billion
CAGR (%) 6.69%

A clear and engaging orientation to recent neurovascular device innovations, clinical adoption drivers, and strategic considerations shaping stakeholder decisions

The landscape of neurovascular intervention devices is evolving rapidly, driven by convergent advances in device engineering, imaging, and acute care pathways. Over the last several years clinicians and device developers have moved from incremental improvements toward platform-level innovations that change how complex cerebrovascular diseases are diagnosed, treated, and managed. These shifts have heightened the imperative for stakeholders to understand not only product-level differentiators but also how procedural workflows, reimbursement dynamics, and care setting preferences interact to shape adoption and outcomes.

This executive summary synthesizes cross-cutting trends and strategic imperatives for manufacturers, clinical leaders, and investors who operate in or adjacent to the neurovascular domain. It situates technology progress-such as enhancements in flow diversion materials and thrombectomy device deliverability-alongside evolving procedural approaches and payer considerations. By clarifying the drivers of clinical adoption and the competitive tensions across product categories and indications, the narrative aims to equip decision-makers with a clear, actionable perspective that supports prioritization of R&D, go-to-market investments, and partnership strategies.

Throughout the following sections, the analysis maintains an emphasis on practical implications, balancing technical detail with commercial context to facilitate rapid translation of insight into operational planning and resource allocation.

How material science breakthroughs, imaging integration, and evolving care delivery models are reshaping device adoption and clinical pathways in neurovascular care

The neurovascular device landscape is undergoing transformative shifts that extend beyond device-level improvements to encompass procedural paradigms and care delivery models. Material science breakthroughs and refined designs have increased device efficacy and safety profiles, enabling clinicians to tackle previously untreatable anatomies and complex lesion morphologies. Simultaneously, enhanced imaging integration and navigation systems have reduced procedural times and improved the precision of device deployment, which in turn has broadened the pool of eligible patients and increased clinician confidence in advanced interventions.

As procedural success rates and operator familiarity grow, new pathways for care are emerging, including expanded utilization in ambulatory surgical settings and the creation of multidisciplinary stroke networks that streamline triage and treatment. These systemic shifts are reinforced by an emphasis on value-based care and outcomes reporting, which incentivize devices and procedural approaches that demonstrably reduce complications, rehospitalizations, and long-term disability. Consequently, companies that align product development with measurable clinical outcomes and streamlined workflows will be better positioned to gain traction.

Finally, collaboration models between device manufacturers and clinical centers are evolving to accelerate real-world evidence generation and iterative device refinement. Strategic partnerships that integrate post-market surveillance, registries, and payer engagement are becoming essential components of commercialization strategies, reshaping how innovations migrate from regulatory approval to routine clinical practice.

Assessing the practical repercussions of new tariff policies on supply chains, procurement decisions, and commercialization strategies across neurovascular device stakeholders

The introduction of tariffs in 2025 for certain medical device components and finished goods has introduced an additional layer of procurement and supply chain complexity for neurovascular device stakeholders. Manufacturers with global manufacturing footprints have been prompted to reassess sourcing strategies and cost structures to mitigate margin erosion and maintain price competitiveness. In turn, procurement teams within health systems and group purchasing organizations are weighing the trade-offs between short-term cost increases and long-term clinical value, particularly for devices that deliver demonstrable reductions in procedure time, complication rates, or subsequent care requirements.

Immediate responses have included a re-evaluation of supplier contracts, increased emphasis on nearshoring or regional manufacturing partnerships, and selective repricing of products where contractual flexibility and payer dynamics permit. In some cases, developers have accelerated investments in design simplification and component consolidation to reduce exposure to tariffed inputs. Meanwhile, clinicians and hospital administrators are focused on preserving procedural continuity and access to best-in-class devices; therefore, strategic communication of health-economic benefits and comparative clinical outcomes has become more critical to offset procurement pressures.

Looking ahead, sustained tariff-related cost pressures will favor organizations that can demonstrate total cost of care benefits, secure resilient supply chains, and adapt commercial strategies to evolving procurement frameworks. Transparent cost-effectiveness evidence and flexible distribution agreements will be pivotal in maintaining market access under shifting trade conditions.

Integrated segmentation insights that reveal how product types, clinical indications, care settings, and procedure types jointly determine adoption dynamics and commercial priorities

The market segmentation framework yields specific insights when product, indication, end user, and procedure perspectives are integrated. Based on product type, device categories such as embolic agents, flow diverters, microcatheters, neurovascular coils, stents, and thrombectomy devices each present distinct clinical and commercial dynamics. Within embolic agents, the distinctions between liquid embolics and particulate embolics influence procedural technique, storage and handling considerations, and clinical use cases. Flow diverters show differentiated value propositions across devices such as the Pipeline Embolization Device and the Surpass Flow Diverter, where differences in deliverability, radial force, and endothelialization profiles affect clinician preference. Microcatheter coatings, whether hydrophilic or polymer-based, change the tactile and navigational characteristics that operators rely upon, while coil technologies that are detachable versus pushable define different trade-offs in deployment control and repositionability. Stent platforms that are balloon-mounted versus self-expanding present distinct lesion preparation and deployment workflows, and thrombectomy strategies split between aspiration devices and stent retrievers, each with specific procedural success patterns that inform institutional purchasing decisions.

When viewed through the lens of indication, aneurysm treatment pathways, arteriovenous malformation interventions, and acute ischemic stroke care place divergent demands on device performance, inventory management, and procedural team composition. End user segmentation-ambulatory centers, clinics, and hospitals-further modulates adoption timelines and procurement behaviors, with ambulatory centers often prioritizing streamlined, high-throughput solutions and hospitals emphasizing versatility and comprehensive inventory to support complex cases. Finally, procedure type segmentation across embolization, flow diversion, and thrombectomy highlights how procedural volume, operator expertise, and case complexity interact to determine device mix and consumable usage.

Taken together, these segmentation lenses underscore the importance of tailoring product design, training programs, and commercial messaging to the nuanced needs of each clinical and operational context, ensuring that innovations are positioned to overcome adoption barriers and deliver measurable clinical impact.

Comparative regional dynamics revealing how regulatory environments, payer structures, and clinical networks drive differentiated adoption and commercialization pathways

Regional dynamics in neurovascular interventions reflect differences in regulatory frameworks, health system architectures, and patterns of clinical practice. In the Americas, advanced stroke systems and robust tertiary care networks have facilitated rapid uptake of endovascular solutions, with a pronounced emphasis on integrating pre-hospital triage and inter-hospital transfer protocols to maximize timely intervention. This region often serves as an early adopter environment for novel devices when backed by strong clinical evidence and health-economic justification, and payers increasingly scrutinize comparative outcomes as part of coverage decisions.

Europe, Middle East & Africa present a heterogeneous landscape where regulatory harmonization in certain markets coexists with variable access and reimbursement policies in others. Clinician networks and center-of-excellence models drive adoption in major urban centers, while translation to broader populations depends on local procurement practices and reimbursement alignment. In some EMEA markets, constrained capital budgets emphasize value-based purchasing and long-term cost-of-care arguments, creating opportunities for devices that demonstrably reduce overall treatment burden.

Asia-Pacific exhibits rapid adoption in high-volume centers alongside growing domestic device development ecosystems. Health systems across the region are investing in stroke infrastructure and advanced neurointerventional training, which supports scaling of both established and newer device categories. However, fragmented regulatory pathways and diverse payer arrangements require nuanced market entry strategies, including local partnerships and region-specific clinical evidence generation. Across all regions, supply chain resilience, regulatory readiness, and evidence tailored to local practice patterns are decisive factors in successful market penetration.

Competitive and collaborative dynamics that determine market leadership through clinical evidence, manufacturing agility, and strategic alignment with health system priorities

Competitive dynamics in neurovascular interventions are shaped by a mix of established device innovators, emerging specialized firms, and vertically integrated healthcare technology companies. Leading organizations typically invest heavily in iterative device refinement, robust clinical trial programs, and broad training initiatives that reduce operator learning curves and accelerate institutional adoption. Meanwhile, smaller, agile firms frequently introduce differentiated materials or delivery mechanisms that challenge incumbents and catalyze category expansion, particularly in niche anatomies or procedural workflows where incremental improvements yield outsized clinical benefit.

Partnerships between device developers and clinical centers of excellence are a common strategic approach to generate real-world evidence and optimize device iterations based on procedural feedback. These collaborative models support faster clinical adoption by building local expertise and producing the outcome data required for payer engagement. Additionally, companies that align their commercial strategies with health system priorities-such as reducing length of stay, decreasing complication rates, or enabling same-day procedures-find it easier to secure formulary inclusion and favorable procurement terms.

Intellectual property strength, manufacturing scalability, and supply chain diversification remain decisive competitive levers. Organizations that demonstrate sustained investment in post-market surveillance, education programs, and integrated clinical support are better positioned to retain market share and expand into adjacent indications and geographies. The most resilient players combine technical excellence with operational fluency across regulatory, reimbursement, and clinical adoption channels.

Actionable strategic and operational recommendations for aligning product design, evidence generation, and commercial execution to secure sustainable adoption and value

Industry leaders should adopt a coordinated strategy that aligns product development, evidence generation, and commercial execution to accelerate adoption and defend market position. Prioritizing design choices that optimize deliverability and procedural efficiency will resonate with clinicians focused on reducing procedure time and improving safety outcomes. Concurrently, investing in robust real-world evidence programs and health-economic analyses will be critical to persuade procurement committees and payers that device selection yields measurable reductions in total cost of care.

Operationally, companies should pursue supply chain resilience by diversifying sourcing, exploring regional manufacturing partnerships, and simplifying bill-of-materials where feasible to mitigate exposure to trade fluctuations. Commercially, tailoring training and support models to end user segmentation-differentiating approaches for ambulatory centers, clinics, and hospitals-will help accelerate adoption while maintaining service quality. Strategic partnerships with leading clinical centers to develop best-practice protocols and case libraries will shorten learning curves and build trust among broader clinician cohorts.

Finally, leadership teams must maintain flexibility in pricing and contracting models to accommodate varied reimbursement environments and procurement processes. Value-based contracting, risk-sharing arrangements, and bundled payment models should be explored where outcomes data support such structures. By integrating clinical, operational, and commercial priorities into a single coherent plan, organizations can convert innovation into sustainable clinical and financial value.

A transparent and multi-method research approach that combines expert interviews, literature synthesis, and scenario testing to ensure robust, actionable insights

The research methodology underpinning this analysis integrates multiple qualitative and quantitative approaches to ensure rigour and relevance. Primary inputs include structured interviews with clinical experts, procurement leaders, and industry executives, which provide contextual understanding of procedural workflows, adoption drivers, and purchasing decision criteria. These conversations are triangulated with a review of peer-reviewed clinical literature, regulatory filings, and conference proceedings to validate performance claims and identify emerging clinical consensus.

Complementary secondary research examines device design trends, manufacturing considerations, and supply chain dynamics, with attention to changes in trade policy and regional regulatory developments. The methodology also incorporates an assessment of reimbursement and health-economic literature to frame adoption incentives and payer perspectives. Data synthesis emphasizes cross-validation across sources and a clear delineation between evidence-based findings and expert opinion, with transparency about the level of confidence for key conclusions.

Where appropriate, scenario analysis is used to explore the implications of policy shifts, supply chain disruptions, and differential adoption rates across care settings. Throughout, the approach prioritizes actionable insight, linking technical device characteristics to operational and commercial outcomes that matter to clinicians, hospital executives, and investors.

Concluding synthesis that connects device innovation, evidence strategy, and operational resilience as the keys to sustainable impact and competitive advantage

In summary, the neurovascular intervention space is transitioning from incremental refinements to transformative innovations that reshape clinical pathways, procurement behaviors, and competitive dynamics. Advances in device design and procedural technology are expanding treatment possibilities and improving outcomes, but successful commercialization increasingly requires integrated strategies that align clinical evidence, supply chain resilience, and payer engagement. The 2025 tariff landscape has amplified the need for nimble sourcing strategies and stronger articulation of total cost of care benefits to maintain market access and clinician adoption.

Segmentation-specific approaches-attuned to product nuances, indication requirements, end-user preferences, and procedural contexts-are essential to prioritize investments and craft persuasive value propositions. Regionally differentiated strategies are equally important, as regulatory, reimbursement, and care delivery frameworks materially influence adoption timing and scale. Companies that combine technical excellence with rigorous evidence programs, adaptable commercial models, and resilient operations will be best positioned to lead.

Ultimately, the path from innovation to standard of care depends on deliberate execution across clinical, commercial, and operational domains. Stakeholders who act proactively to align these elements will capture the greatest value and contribute meaningfully to improved patient outcomes in neurovascular care.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Neurovascular Intervention Devices Market, by Product Type

  • 8.1. Embolic Agents
    • 8.1.1. Liquid Embolics
    • 8.1.2. Particulate Embolics
  • 8.2. Flow Diverters
    • 8.2.1. Pipeline Embolization Device
    • 8.2.2. Surpass Flow Diverter
  • 8.3. Microcatheters
    • 8.3.1. Hydrophilic Coated
    • 8.3.2. Polymer Coated
  • 8.4. Neurovascular Coils
    • 8.4.1. Detachable Coils
    • 8.4.2. Pushable Coils
  • 8.5. Stents
    • 8.5.1. Balloon Mounted
    • 8.5.2. Self Expanding
  • 8.6. Thrombectomy Devices
    • 8.6.1. Aspiration Devices
    • 8.6.2. Stent Retriever

9. Neurovascular Intervention Devices Market, by Indication

  • 9.1. Aneurysm
  • 9.2. Arteriovenous Malformation
  • 9.3. Stroke

10. Neurovascular Intervention Devices Market, by Procedure Type

  • 10.1. Embolization
  • 10.2. Flow Diversion
  • 10.3. Thrombectomy

11. Neurovascular Intervention Devices Market, by End User

  • 11.1. Ambulatory Centers
  • 11.2. Clinics
  • 11.3. Hospitals

12. Neurovascular Intervention Devices Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Neurovascular Intervention Devices Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Neurovascular Intervention Devices Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Neurovascular Intervention Devices Market

16. China Neurovascular Intervention Devices Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Abbott Laboratories
  • 17.6. Acandis GmbH
  • 17.7. Balt Group
  • 17.8. Becton, Dickinson and Company
  • 17.9. Boston Scientific Corporation
  • 17.10. Carl Zeiss AG
  • 17.11. Evasc Medical Systems Corp.
  • 17.12. GE Healthcare
  • 17.13. Imperative Care Inc.
  • 17.14. Japan Lifeline Co.
  • 17.15. Johnson & Johnson Services, Inc.
  • 17.16. Kaneka Corporation
  • 17.17. Koninklijke Philips N.V.
  • 17.18. LivaNova PLC
  • 17.19. Medikit Co., Ltd.
  • 17.20. Medtronic plc
  • 17.21. MicroPort Scientific Corporation
  • 17.22. MicroVention, Inc.
  • 17.23. Nanoflex Robotics AG
  • 17.24. Penumbra, Inc.
  • 17.25. Phenox GmbH by Wallaby Medical, LLC
  • 17.26. Rapid Medical Ltd.
  • 17.27. Stryker Corporation
  • 17.28. Terumo Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PROCEDURE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY EMBOLIC AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY EMBOLIC AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY EMBOLIC AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY EMBOLIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY LIQUID EMBOLICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY LIQUID EMBOLICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY LIQUID EMBOLICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PARTICULATE EMBOLICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PARTICULATE EMBOLICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PARTICULATE EMBOLICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY FLOW DIVERTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY FLOW DIVERTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY FLOW DIVERTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY FLOW DIVERTERS, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PIPELINE EMBOLIZATION DEVICE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PIPELINE EMBOLIZATION DEVICE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PIPELINE EMBOLIZATION DEVICE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY SURPASS FLOW DIVERTER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY SURPASS FLOW DIVERTER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY SURPASS FLOW DIVERTER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY MICROCATHETERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY MICROCATHETERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY MICROCATHETERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY MICROCATHETERS, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY HYDROPHILIC COATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY HYDROPHILIC COATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY HYDROPHILIC COATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY POLYMER COATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY POLYMER COATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY POLYMER COATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY NEUROVASCULAR COILS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY NEUROVASCULAR COILS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY NEUROVASCULAR COILS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY NEUROVASCULAR COILS, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY DETACHABLE COILS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY DETACHABLE COILS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY DETACHABLE COILS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PUSHABLE COILS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PUSHABLE COILS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PUSHABLE COILS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY STENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY STENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY STENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY STENTS, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY BALLOON MOUNTED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY BALLOON MOUNTED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY BALLOON MOUNTED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY SELF EXPANDING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY SELF EXPANDING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY SELF EXPANDING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY THROMBECTOMY DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY THROMBECTOMY DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY THROMBECTOMY DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY THROMBECTOMY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY ASPIRATION DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY ASPIRATION DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY ASPIRATION DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY STENT RETRIEVER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY STENT RETRIEVER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY STENT RETRIEVER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY ANEURYSM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY ANEURYSM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY ANEURYSM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY ARTERIOVENOUS MALFORMATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY ARTERIOVENOUS MALFORMATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY ARTERIOVENOUS MALFORMATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY STROKE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY STROKE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY STROKE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY EMBOLIZATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY EMBOLIZATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY EMBOLIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY FLOW DIVERSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY FLOW DIVERSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY FLOW DIVERSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY THROMBECTOMY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY THROMBECTOMY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY THROMBECTOMY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY AMBULATORY CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY AMBULATORY CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY AMBULATORY CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. AMERICAS NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 95. AMERICAS NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 96. AMERICAS NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY EMBOLIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 97. AMERICAS NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY FLOW DIVERTERS, 2018-2032 (USD MILLION)
  • TABLE 98. AMERICAS NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY MICROCATHETERS, 2018-2032 (USD MILLION)
  • TABLE 99. AMERICAS NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY NEUROVASCULAR COILS, 2018-2032 (USD MILLION)
  • TABLE 100. AMERICAS NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY STENTS, 2018-2032 (USD MILLION)
  • TABLE 101. AMERICAS NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY THROMBECTOMY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 102. AMERICAS NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 103. AMERICAS NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 104. AMERICAS NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. NORTH AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. NORTH AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY EMBOLIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 108. NORTH AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY FLOW DIVERTERS, 2018-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY MICROCATHETERS, 2018-2032 (USD MILLION)
  • TABLE 110. NORTH AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY NEUROVASCULAR COILS, 2018-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY STENTS, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY THROMBECTOMY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 114. NORTH AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 116. LATIN AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. LATIN AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. LATIN AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY EMBOLIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY FLOW DIVERTERS, 2018-2032 (USD MILLION)
  • TABLE 120. LATIN AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY MICROCATHETERS, 2018-2032 (USD MILLION)
  • TABLE 121. LATIN AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY NEUROVASCULAR COILS, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY STENTS, 2018-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY THROMBECTOMY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 124. LATIN AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY EMBOLIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY FLOW DIVERTERS, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY MICROCATHETERS, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY NEUROVASCULAR COILS, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY STENTS, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY THROMBECTOMY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY EMBOLIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY FLOW DIVERTERS, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY MICROCATHETERS, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY NEUROVASCULAR COILS, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY STENTS, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY THROMBECTOMY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 149. MIDDLE EAST NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. MIDDLE EAST NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. MIDDLE EAST NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY EMBOLIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 152. MIDDLE EAST NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY FLOW DIVERTERS, 2018-2032 (USD MILLION)
  • TABLE 153. MIDDLE EAST NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY MICROCATHETERS, 2018-2032 (USD MILLION)
  • TABLE 154. MIDDLE EAST NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY NEUROVASCULAR COILS, 2018-2032 (USD MILLION)
  • TABLE 155. MIDDLE EAST NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY STENTS, 2018-2032 (USD MILLION)
  • TABLE 156. MIDDLE EAST NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY THROMBECTOMY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 157. MIDDLE EAST NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 158. MIDDLE EAST NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 159. MIDDLE EAST NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 160. AFRICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 161. AFRICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. AFRICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY EMBOLIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 163. AFRICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY FLOW DIVERTERS, 2018-2032 (USD MILLION)
  • TABLE 164. AFRICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY MICROCATHETERS, 2018-2032 (USD MILLION)
  • TABLE 165. AFRICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY NEUROVASCULAR COILS, 2018-2032 (USD MILLION)
  • TABLE 166. AFRICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY STENTS, 2018-2032 (USD MILLION)
  • TABLE 167. AFRICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY THROMBECTOMY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 168. AFRICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 169. AFRICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 170. AFRICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 171. ASIA-PACIFIC NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. ASIA-PACIFIC NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. ASIA-PACIFIC NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY EMBOLIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 174. ASIA-PACIFIC NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY FLOW DIVERTERS, 2018-2032 (USD MILLION)
  • TABLE 175. ASIA-PACIFIC NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY MICROCATHETERS, 2018-2032 (USD MILLION)
  • TABLE 176. ASIA-PACIFIC NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY NEUROVASCULAR COILS, 2018-2032 (USD MILLION)
  • TABLE 177. ASIA-PACIFIC NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY STENTS, 2018-2032 (USD MILLION)
  • TABLE 178. ASIA-PACIFIC NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY THROMBECTOMY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 179. ASIA-PACIFIC NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 180. ASIA-PACIFIC NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 181. ASIA-PACIFIC NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 182. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 183. ASEAN NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. ASEAN NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. ASEAN NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY EMBOLIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 186. ASEAN NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY FLOW DIVERTERS, 2018-2032 (USD MILLION)
  • TABLE 187. ASEAN NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY MICROCATHETERS, 2018-2032 (USD MILLION)
  • TABLE 188. ASEAN NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY NEUROVASCULAR COILS, 2018-2032 (USD MILLION)
  • TABLE 189. ASEAN NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY STENTS, 2018-2032 (USD MILLION)
  • TABLE 190. ASEAN NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY THROMBECTOMY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 191. ASEAN NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 192. ASEAN NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 193. ASEAN NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 194. GCC NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 195. GCC NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 196. GCC NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY EMBOLIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 197. GCC NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY FLOW DIVERTERS, 2018-2032 (USD MILLION)
  • TABLE 198. GCC NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY MICROCATHETERS, 2018-2032 (USD MILLION)
  • TABLE 199. GCC NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY NEUROVASCULAR COILS, 2018-2032 (USD MILLION)
  • TABLE 200. GCC NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY STENTS, 2018-2032 (USD MILLION)
  • TABLE 201. GCC NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY THROMBECTOMY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 202. GCC NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 203. GCC NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. GCC NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPEAN UNION NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPEAN UNION NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPEAN UNION NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY EMBOLIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPEAN UNION NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY FLOW DIVERTERS, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPEAN UNION NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY MICROCATHETERS, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPEAN UNION NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY NEUROVASCULAR COILS, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPEAN UNION NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY STENTS, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPEAN UNION NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY THROMBECTOMY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPEAN UNION NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPEAN UNION NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPEAN UNION NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 216. BRICS NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 217. BRICS NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 218. BRICS NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY EMBOLIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 219. BRICS NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY FLOW DIVERTERS, 2018-2032 (USD MILLION)
  • TABLE 220. BRICS NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY MICROCATHETERS, 2018-2032 (USD MILLION)
  • TABLE 221. BRICS NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY NEUROVASCULAR COILS, 2018-2032 (USD MILLION)
  • TABLE 222. BRICS NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY STENTS, 2018-2032 (USD MILLION)
  • TABLE 223. BRICS NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY THROMBECTOMY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 224. BRICS NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 225. BRICS NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 226. BRICS NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 227. G7 NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 228. G7 NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 229. G7 NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY EMBOLIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 230. G7 NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY FLOW DIVERTERS, 2018-2032 (USD MILLION)
  • TABLE 231. G7 NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY MICROCATHETERS, 2018-2032 (USD MILLION)
  • TABLE 232. G7 NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY NEUROVASCULAR COILS, 2018-2032 (USD MILLION)
  • TABLE 233. G7 NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY STENTS, 2018-2032 (USD MILLION)
  • TABLE 234. G7 NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY THROMBECTOMY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 235. G7 NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 236. G7 NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 237. G7 NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 238. NATO NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 239. NATO NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 240. NATO NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY EMBOLIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 241. NATO NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY FLOW DIVERTERS, 2018-2032 (USD MILLION)
  • TABLE 242. NATO NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY MICROCATHETERS, 2018-2032 (USD MILLION)
  • TABLE 243. NATO NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY NEUROVASCULAR COILS, 2018-2032 (USD MILLION)
  • TABLE 244. NATO NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY STENTS, 2018-2032 (USD MILLION)
  • TABLE 245. NATO NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY THROMBECTOMY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 246. NATO NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 247. NATO NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 248. NATO NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 249. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 250. UNITED STATES NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 251. UNITED STATES NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 252. UNITED STATES NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY EMBOLIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 253. UNITED STATES NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY FLOW DIVERTERS, 2018-2032 (USD MILLION)
  • TABLE 254. UNITED STATES NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY MICROCATHETERS, 2018-2032 (USD MILLION)
  • TABLE 255. UNITED STATES NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY NEUROVASCULAR COILS, 2018-2032 (USD MILLION)
  • TABLE 256. UNITED STATES NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY STENTS, 2018-2032 (USD MILLION)
  • TABLE 257. UNITED STATES NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY THROMBECTOMY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 258. UNITED STATES NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 259. UNITED STATES NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 260. UNITED STATES NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 261. CHINA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 262. CHINA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 263. CHINA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY EMBOLIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 264. CHINA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY FLOW DIVERTERS, 2018-2032 (USD MILLION)
  • TABLE 265. CHINA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY MICROCATHETERS, 2018-2032 (USD MILLION)
  • TABLE 266. CHINA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY NEUROVASCULAR COILS, 2018-2032 (USD MILLION)
  • TABLE 267. CHINA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY STENTS, 2018-2032 (USD MILLION)
  • TABLE 268. CHINA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY THROMBECTOMY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 269. CHINA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 270. CHINA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 271. CHINA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)